Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...

Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

After 6 months of hormone therapy, men with prostate cancer showed worsening lipid profiles, with 21% showing increased risk of cardiovascular disease based on general population tools. Men receiving ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

Thousands of men battling prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...